NCT00049517 2023-06-15
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Eastern Cooperative Oncology Group
Phase 3 Completed
Clinical Trials
7 trialsNCT00551460 2023-01-10
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00372593 2021-03-24
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Children's Oncology Group
Phase 3 Completed
NCT00085709 2015-09-30
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
SWOG Cancer Research Network
Phase 3 Completed
NCT00274781 2015-07-10
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
The Cleveland Clinic
Phase 2 Completed
NCT00882102 2013-09-13
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00968071 2013-03-08
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed